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Abstract Background: Antiplatelet agents are used during endovascular treatment of
cerebral aneurysms to prevent thromboembolic complications.
Objective: The aim of this study was to investigate the efficacy of clopidogrel
for the prevention of thromboembolic complications during elective coil
embolization of unruptured cerebral aneurysms.
Methods: Sixty-three patients prospectively received oral clopidogrel 75mg/day
from 3 days before and for 1 day after the procedure at our institute (Kohnan
Hospital, Sendai, Japan) during 2007.
Results: At 24 hours post-coiling, significantly less high-intensity areas, de-
tected by MRI with diffusion-weighted imaging (MRI-DWI), were observed
in clopidogrel-treated patients compared with a historical control cohort of
aspirin (acetylsalicylic acid)-treated patients (13/63 [20.6%] vs 27/69 [39.1%];
p = 0.02), primarily due to a statistically significantly lower rate during repair
of small (<10mm) lesions (p= 0.008). Also, the rate of periprocedural thrombo-
embolic events was lower in the clopidogrel than the aspirin cohort (2/63
[3.2%] vs 5/69 [7.2%]; p = 0.3).
Conclusions: Clopidogrel was generally well tolerated with no signs of hem-
orrhagic complications or liver dysfunction.
Background
Intracranial aneurysms are reported to occur
in 1–10% of the population and are associated
with considerable morbidity and mortality fol-
lowing rupture.[1-3] The estimated rate of aneu-
rysm rupture ranges between 0–2% per year, and
is dependent on factors such as family history and
the size and location of the aneurysm; small
aneurysms (<10mm in diameter) in arteries in the
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front of the brain carry a lower risk than those in
arteries at the rear of the brain.[3-5]
Since its introduction in clinical practice in the
1990s, endovascular coiling for the treatment of
cerebral aneurysms has gained widespread use.[4,6]
Noninvasive coil embolization for an unruptured
aneurysm is relatively safe compared with invasive
surgical treatment such as aneurysmal clipping.[3,4]
The structure of the platinum coil adjacent to the in-
timal surface of the artery facilitates the reconstruction
of the parent artery by stimulating endothelial
growth that promotes stasis, platelet adhesion,
clotting, thrombosis, and occlusion of the aneu-
rysm, resulting in blood flow remodeling.[7]
Improvements in techniques and management
in recent years have facilitated a reduction in
procedural risks associated with coil embolization
for unruptured cerebral aneurysms;[6,8] however,
acute and delayed thromboembolic events,[9] in-
cluding stroke and transient ischemic attacks (TIA),
remain themost common clinical complications[6,10]
with reported incidence rates of 4–28%.[11,12] Im-
portantly, the incidence of thromboembolic events
associatedwith aneurysm coiling does not appear to
be related to the size and location of the aneurysm,
the number of coils used, patient age, or timing of
embolization, and it has been suggested that anti-
coagulationmay play a pivotal role in prevention.[13]
However, heparin alone has been shown to be lim-
ited in preventing thromboembolic events following
aneurysm coiling.[13]
Aspirin (acetylsalicylic acid) and clopidogrel
(Plavix) are used in the management of elective
endovascular treatment of cerebral aneurysms to
prevent thromboembolic complications despite a
lack of robust data to support this approach.[14,15]
Although aspirin has shown efficacy in reducing
the risk of intraoperative atherothrombotic com-
plications, the antiplatelet agent is associated with
insufficient inhibition of platelet aggregation
under shear stress, and an increased risk of gas-
trointestinal bleeding.[16,17] Clopidogrel may be a
favorable alternative to aspirin as it has demon-
strated greater efficacy in reducing thromboem-
bolic events and less safety issues in patients with
vascular disease.[18]
The majority of thromboembolic complica-
tions associated with endovascular procedures
occur perioperatively, which coincides with the
period of maximal local prothrombotic activity,
i.e. the initial 24 hours; antiplatelet therapy ini-
tiated before and/or during intervention may di-
minish thrombus formation.[9,13,19] Therefore, in
this current historical control study, we sought to
compare the efficacy of clopidogrel with that of
aspirin for reduction in risk of periprocedural
thromboembolic complications resulting from
elective coil embolization for unruptured cerebral
aneurysms by evaluating abnormal high-intensity
areas (HIA) diagnostic of ischemic lesions, i.e.
restricted diffusion or silent ischemia, at 24 hours
after the procedure.
Methods
Prospective data from the use of clopidogrel
during coil embolization for unruptured cerebral
aneurysms, collected from January 2007 through
to December 2007 (clopidogrel was approved in
Japan in 2006 and 2007 for use in stroke and
acute coronary syndromes [ACS], respectively),
were compared with retrospective data on the use
of aspirin for the same procedure collected from
February 2005 to December 2006. This study was
conducted at Kohnan Hospital, Sendai, Japan,
and the local ethics committee provided approval
prior to study initiation.
Eligible patients included those with signs and
symptoms of suspected cerebral aneurysm who
were evaluated and, following confirmation with
imaging using either CT or MRI, were scheduled
to undergo elective coil embolization for an un-
ruptured cerebral aneurysm. Study inclusion was
dependent on full clinical assessments including
health status and life expectancy. Informed con-
sent was required prior to the procedure.Datawere
collected on patient history of previous aneurysms
(ruptured or unruptured). Exclusion criteria in-
cluded allergy or intolerance to aspirin, clopidog-
rel or platinum, contraindication for MRI, e.g.
pacemaker/implantable cardioverter defibrillator
or any other metal implants within the body.
All patients underwent diagnostic angiography
prior to intervention at which time aneurysm size
and locationwere ascertained. Before the procedure,
patients received anticoagulation with intravenous
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heparin 5000 units and during the procedure, hep-
arin 1000 units/hour for a targeted activated clotting
time of 200 seconds.
Patients prospectively received clopidogrel
75mg/day beginning 3 days prior to, and for 1 day
following coiling. The historical control cohort com-
prised consecutive patients who had received oral
aspirin 100mg/day according to the same schedule
during the period 2005-6, prior to the approval of
clopidogrel. The dosages of aspirin and clopidogrel
in this study are those approved for use in stroke or
for maintenance therapy of ACS in Japan.
Coil embolization procedures were performed
with suitable guiding catheters, microcatheters and
coils for each patient under general anesthesia by a
neuroanesthesiologist. Balloon neck plasty was also
performed, if necessary, for wide neck aneurysms.
Information used from patient charts included
date of birth, date of procedure, number of previous
aneurysms, aneurysm size, antiplatelet therapy and
timing of use (before and/or during intervention) and
results of follow-up angiography. Post-procedure,
patients were taken to a neurological suite for re-
covery and neurological status and symptoms were
monitored by an independent neurologist.
The primary efficacy endpoints were peri-
procedural thromboembolic events, which were
evaluated as thrombus formation and neurological
deficits, either TIA or permanent. Abnormal HIA
were detected byMRI examination with diffusion-
weighted imaging (DWI) [MRI-DWI] at 24 hours
after coil embolization using a 3T-MRI scanner
(General Electric Company, Fairfield, CT, USA).
Images were read in a blinded manner by two
specialists in neuroendovascular therapywhowere
board-certified in Japan. For patient background
data, between-group differences were assessed by
the w2 test. Outcomes were also compared with a
w2 test. Statistical calculations were performed using
a standard statistical software package (Statemate
2.0; GraphPad Software, Inc., San Diego, CA,
USA). Differences in results were considered to be
statistically significant if the p-value was <0.05.
Results
Retrospective analysis of data from our in-
stitute identified 69 consecutive patients, 16 males
and 53 females, who had received aspirin, while
during the prospective analysis, 63 consecutive
patients, 20 males and 43 females, received clo-
pidogrel treatment for endovascular coil emboli-
zation of an unruptured cerebral aneurysm; the
evaluable population comprised 132 patients of
mean age 59 years. Baseline patient characteristics
and aneurysm location and size did not differ
significantly between treatment groups (table I).
The majority of aneurysms in both cohorts were
located in the internal carotid artery and were
<10mm in size.
The incidence of HIA assessed by MRI-DWI
at 24 hours after coiling was significantly lower
with clopidogrel than aspirin (20.6% vs 39.1%;
p = 0.02) [figure 1]; ischemic lesions were detected
in 13/63 clopidogrel-treated compared with 27/69
aspirin-treated patients. Notably, the rate of HIA
occurrence was statistically significantly lower in
clopidogrel- than aspirin-treated patients for small
(<10mm) lesions (8/54 [14.8%] vs 22/60 [36.7%];
p = 0.008), while for larger (‡10mm) lesions, the
rate was also markedly reduced (3/9 [33.3%] vs
5/9 [55.6%]); however, statistical significance was
not shown although this may have been due to
the small size of these cohorts (figure 2).










58.9 (24-85) 59.0 (36-79)
Gender [n (%)]
Female 53 (77) 43 (68) NS
Male 16 (23) 20 (32)
Aneurysm location (n)






<10 60 54 NS
‡10 9 9
ACA = anterior cerebral artery; ICA = internal carotid artery; MCA =
middle cerebral artery; NS = not significant; VA-BA = vertebral
artery-basilar artery.
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Assessment of the occurrence of symptomatic
TIA or stroke showed that compared with aspirin
treatment, the rate of periprocedural thromboem-
bolic events was lower in the cohort that received
clopidogrel (2/63 [3.2%] vs 5/69 [7.2%]; p= 0.30)
[figure 3]. Unfortunately, one patient in the clo-
pidogrel-treated group had hemiparesis follow-
ing the procedure, but other patients showed no
signs of symptomatic infarction, even in the pre-
sence of a lesion found by MRI-DWI.
An example case is shown in figure 4. An un-
ruptured anterior communicating artery aneurysm
was treated by coil embolization with clopidogrel
treatment. Clot formation occurred in the parent
arteries during coiling. Percutaneous transluminal
angioplasty was performed immediately and the
clot was subsequently cleared away. Even though
MRI-DWI revealed a small lesion at the right
frontal lobe on day 1 post-procedure, the patient
had no neurologic deficits.
Clopidogrel was well tolerated in patients un-
dergoing coil embolization for unruptured cere-
bral aneurysm; no hemorrhagic complications or
bleeding were identified and there were no signs
of liver dysfunction, as assessed by biochemical
laboratory blood assays.
Discussion
This study showed a greater antithrombotic effect
with clopidogrel than with aspirin treatment (his-
torical control) in patients undergoing elective coil
embolization for an unruptured cerebral aneurysm.
The incidence of abnormal HIA assessed by
MRI-DWI at 24 hours after coiling was signi-
ficantly lower with clopidogrel than with aspirin
treatment (p = 0.02), and there were less peripro-
cedural thromboembolic events with clopidogrel,
although this was not statistically significant
(p = 0.30).
Management guidelines recommend surgical
or endovascular intervention for the treatment of
an unruptured intracranial aneurysm.[20-22] It is
well established that thromboembolic events are
the most common complications arising during or
after aneurysm coiling.[11,12] Both the catheter and
the coil mass are a potential source for thrombus
formation where clotting may occur.[11,13,14]
A number of studies that used MRI-DWI for
detection of early ischemia associatedwithGuglielmi




























Fig. 1. Incidence of high-intensity areas (HIA) assessed by MRI
with diffusion-weighted imaging at 24 hours post-coil embolization
for unruptured cerebral aneurysm following aspirin (acetylsalicylic




























Fig. 2. Frequency of high-intensity areas by aneurysm size (< or
‡10mm) at 24 hours post-coil embolization for unruptured cere-
bral aneurysm following aspirin (acetylsalicylic acid) or clopidogrel
treatment.
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cerebral aneurysms showed a high rate of silent
thromboembolic events, 42%,[13] 49%,[23] and 61%.[11]
Although subsequent clinical outcomes of such
events are rare,[11] antiplatelet agents are a safe op-
tion for reduction in the risk of thromboembolic
events, asymptomatic or symptomatic.[11,13]
In one study, compared with no antiplatelet ther-
apy, there was a significant reduction in thrombo-
embolic events with intravenous aspirin (8.8% vs
17.6%; p= 0.028) with no increase in intraop-
erative bleeding during endovascular treatment
of 247 patients with ruptured or unruptured cerebral
aneurysms.[14] Similarly, a retrospective analysis
of 10-year data from 369 patients who underwent
elective coil embolization of unruptured cerebral
aneurysms showed that compared with no anti-
platelet treatment (16%), the rate of symptomatic
thromboembolic events was significantly lower in
patients who received oral aspirin and/or clopi-
dogrel treatment (2%; p= 0.004), especially when
administered pre- and post-procedure versus only
post-procedure (1.9% vs 2.3%).[15] In addition, recent
retrospective analyses of trials of oral antiplatelet
treatment (clopidogrel,[24,25] aspirin,[25] or both[25])
given prior to, but not following, coil emboliza-
tion of unruptured cerebral aneurysms showed
trends in reduction (7.4% vs 12.6%; p= 0.05)[24] or
significant (2.1% vs 12.8%; p= 0.023)[25] reductions
in perioperative thromboembolic complications,
with no increase in hemorrhagic complication
rates. It must be noted that these trials differed in
design compared with each other and in com-
parison with our current trial, both were large
trials that provided baseline stratified risks for
thromboembolic complications. The availability
of new consensus recommendations for reporting
standards for endovascular treatment of intra-
cranial aneurysms may facilitate the publication
of trial results amenable for direct comparison.[26]
Clopidogrel is approved to reduce thrombotic
events in a number of indications including ACS,
stroke, myocardial infarction, and ischemic heart
disorders. The current study highlights the bene-
fits of clopidogrel compared with aspirin for pro-
phylaxis of thromboembolic complications during
aneurysm coiling. Although there was no signif-
icant between-treatment difference in the incidence



























Fig. 3. Incidence of periprocedural thromboembolic events.
a b c d
Fig. 4. An unruptured anterior communicating artery aneurysm in digital subtraction angiography (a) before and (b) during coil embolization
showing clot formation occurring in both the right and left anterior cerebral artery at the end of the procedure, and (c) following percutaneous
transluminal angiography that was performed immediately (the clot was subsequently cleared away). (d) Diffusion-weighted MRI revealed
a small lesion at the right frontal lobe on day 1 after the procedure; however, the patient had no neurologic deficits.
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important to reduce such events. In contrast with
aspirin, which enhances shear stress-induced platelet
aggregation, clopidogrel is known to inhibit shear
stress-induced, as well as adenosine diphosphate-
dependent, platelet aggregation.[19] In this respect,
clopidogrel has greater potential to inhibit plate-
let function more effectively, which may account
for the present results. Future studies with larger
sample populations may allow potential between-
group differences to be detected.
Our study is not without limitations, including:
a study population derived fromboth retrospective
and prospective data; short-term follow-up; the
absence of platelet function assays to assess re-
sistance to antiplatelet treatment; practice effects
such as increased operator experience over time
or use of balloon- or stent-assisted coil treatment,
which may have influenced observed results; and
the presence of confounding factors (e.g. patient
co-morbidities such as cardiovascular [including
smoking history] or atherosclerotic [presence of
atherosclerosis/previous stroke] risk factors) that
could not be ruled out as influences contributing
to thromboembolic events in affected patients.
Conclusion
The results of our study suggest that clopido-
grel is an effective and well tolerated antiplatelet
agent in patients undergoing coil embolization of
an unruptured cerebral aneurysm. Previous ex-
perience with aspirin suggests that clopidogrel may
offer superior short-term benefit, which needs to
be evaluated in a robustly designed, larger pro-
spective trial that would allow the inclusion of a
sufficient number of patients with unruptured
cerebral aneurysms, including those with large
aneurysms, to derive a statistically definitive
result.
Acknowledgments
The authors would like to thank Nila Bhana, MSc, of
inScience Communications, a Wolters Kluwer business, for
providing medical writing support funded by sanofi-aventis,
Japan.
The authors have no conflicts of interest that are directly
relevant to the content of this study.
References
1. Wanke I, Doerfler A, Dietrich U, et al. Endovascular treat-
ment of unruptured intracranial aneurysms. AJNR Am
J Neuroradiol 2002 May; 23 (5): 756-61
2. Meyer FB, Morita A, Puumala MR, et al. Medical and
surgical management of intracranial aneurysms. Mayo
Clin Proc 1995 Feb; 70 (2): 153-72
3. Wiebers DO, Whisnant JP, Huston 3rd J, et al. Unruptured
intracranial aneurysms: natural history, clinical outcome,
and risks of surgical and endovascular treatment. Lancet
2003 Jul 12; 362 (9378): 103-10
4. Brisman JL, Song JK, Newell DW. Cerebral aneurysms.
N Engl J Med 2006 Aug 31; 355 (9): 928-39
5. Brown Jr RD, Huston J, Hornung R, et al. Screening for
brain aneurysm in the Familial Intracranial Aneurysm
study: frequency and predictors of lesion detection.
J Neurosurg 2008 Jun; 108 (6): 1132-8
6. Lanterna LA, Tredici G, Dimitrov BD, et al. Treatment of
unruptured cerebral aneurysms by embolization with gu-
glielmi detachable coils: case-fatality, morbidity, and ef-
fectiveness in preventing bleeding – a systematic review of
the literature. Neurosurgery 2004 Oct; 55 (4): 767-75; dis-
cussion 75-8
7. Ansari SA, Lassig JP, Nicol E, et al. Thrombosis of a fusi-
form intracranial aneurysm induced by overlapping neu-
roform stents: case report. Neurosurgery 2007 May; 60 (5):
E950-1; discussion E-1
8. van Rooij WJ, Sluzewski M. Procedural morbidity and
mortality of elective coil treatment of unruptured intra-
cranial aneurysms. AJNR Am J Neuroradiol 2006 Sep; 27
(8): 1678-80
9. Qureshi AI, Luft AR, Sharma M, et al. Prevention and
treatment of thromboembolic and ischemic complications
associated with endovascular procedures: part II – clinical
aspects and recommendations. Neurosurgery 2000 Jun; 46
(6): 1360-75; discussion 75-6
10. Bendok BR, Hanel RA, Hopkins LN. Coil embolization of
intracranial aneurysms. Neurosurgery 2003 May; 52 (5):
1125-30; discussion 30
11. Rordorf G, Bellon RJ, Budzik Jr RE, et al. Silent thrombo-
embolic events associated with the treatment of unruptured
cerebral aneurysms by use of Guglielmi detachable coils:
prospective study applying diffusion-weighted imaging.
AJNR Am J Neuroradiol 2001 Jan; 22 (1): 5-10
12. Brooks NP, Turk AS, Niemann DB, et al. Frequency of
thromboembolic events associated with endovascular
aneurysm treatment: retrospective case series. J Neurosurg
2008 Jun; 108 (6): 1095-100
13. Grunwald IQ, Papanagiotou P, Politi M, et al. Endovascular
treatment of unruptured intracranial aneurysms: occur-
rence of thromboembolic events. Neurosurgery 2006 Apr;
58 (4): 612-8; discussion 8
14. Ries T, Buhk JH, Kucinski T, et al. Intravenous administra-
tion of acetylsalicylic acid during endovascular treatment of
cerebral aneurysms reduces the rate of thromboembolic
events. Stroke 2006 Jul; 37 (7): 1816-21
15. Yamada NK, Cross 3rd DT, Pilgram TK, et al. Effect of
antiplatelet therapy on thromboembolic complications of
elective coil embolization of cerebral aneurysms. AJNR
Am J Neuroradiol 2007 Oct; 28 (9): 1778-82
6 Matsumoto et al.
ª 2012 Matsumoto et al., publisher and licensee Adis Data Information BV. Drugs R D 2012; 12 (1)
16. Antithrombotic Trialists’ Collaboration. Collaborative meta-
analysis of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and stroke in
high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
17. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment
with clopidogrel and aspirin followed by long-term therapy
in patients undergoing percutaneous coronary inter-
vention: the PCI-CURE study. Lancet 2001 Aug 18; 358
(9281): 527-33
18. A randomised, blinded, trial of clopidogrel versus aspirin in
patients at risk of ischaemic events (CAPRIE). CAPRIE
Steering Committee. Lancet 1996 Nov 16; 348 (9038):
1329-39
19. Qureshi AI, Luft AR, Sharma M, et al. Prevention and
treatment of thromboembolic and ischemic complications
associated with endovascular procedures: Part I–Patho-
physiological and pharmacological features. Neurosurgery
2000 Jun; 46 (6): 1344-59
20. Bederson JB, Awad IA, Wiebers DO, et al. Recommend-
ations for the management of patients with unruptured
intracranial aneurysms : a statement for healthcare pro-
fessionals from the Stroke Council of the American Heart
Association. Circulation 2000 Oct 31; 102 (18): 2300-8
21. Johnston SC, Higashida RT, Barrow DL, et al. Recommend-
ations for the endovascular treatment of intracranial aneu-
rysms: a statement for healthcare professionals from the
Committee on Cerebrovascular Imaging of the American
Heart Association Council on Cardiovascular Radiology.
Stroke 2002 Oct; 33 (10): 2536-44
22. Meyers PM, Schumacher HC, Higashida RT, et al. In-
dications for the performance of intracranial endovascular
neurointerventional procedures: a scientific statement from
the American Heart Association Council on Cardio-
vascular Radiology and Intervention, Stroke Council,
Council on Cardiovascular Surgery and Anesthesia, In-
terdisciplinary Council on Peripheral Vascular Disease,
and Interdisciplinary Council on Quality of Care and
Outcomes Research. Circulation 2009 Apr 28; 119 (16):
2235-49
23. Soeda A, Sakai N, Sakai H, et al. Thromboembolic events
associated with Guglielmi detachable coil embolization of
asymptomatic cerebral aneurysms: evaluation of 66 con-
secutive cases with use of diffusion-weighted MR imaging.
AJNR Am J Neuroradiol 2003 Jan; 24 (1): 127-32
24. Kang HS, Han MH, Kwon BJ, et al. Is clopidogrel pre-
medication useful to reduce thromboembolic events during
coil embolization for unruptured intracranial aneurysms?
Neurosurgery 2010 Nov; 67 (5): 1371-6; discussion 6
25. Hwang G, Jung C, Park SQ, et al. Thromboembolic com-
plications of elective coil embolization of unruptured
aneurysms: the effect of oral antiplatelet preparation on
periprocedural thromboembolic complication. Neuro-
surgery 2010 Sep; 67 (3): 743-8; discussion 8
26. Meyers PM, Schumacher HC, Higashida RT, et al. Re-
porting standards for endovascular repair of saccular
intracranial cerebral aneurysms. AJNR Am J Neuroradiol
2010 January 1; 31 (1): E12-24
Correspondence: Dr Yasushi Matsumoto, Department of
Neuroendovascular Therapy, Kohnan Hospital, 4-20-1
Nagamachi-minami, Taihaku-ku, Sendai, 982-8523, Japan.
E-mail: matsumoto@kohnan-sendai.or.jp
Antiplatelets for Coil Embolization of Cerebral Aneurysm 7
ª 2012 Matsumoto et al., publisher and licensee Adis Data Information BV. Drugs R D 2012; 12 (1)
